#Izalontamab
LightNews LightNews
vcclibrary.bsky.social
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials. www.annalsofoncology.org/article/S092...
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials
Therapeutic options after progression on EGFR tyrosine kinase inhibitors (TKIs) remain limited for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Izalontamab brengitecan (Iza-bren; BL-...
www.annalsofoncology.org
January 29, 2026 at 12:49 PM
eliogreg.bsky.social
#Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with #EGFR-mutated #NSCLC: Pooled analysis of phase 1 and phase 2 trials

www.annalsofoncology.org/article/S092...
January 28, 2026 at 5:38 AM
aacrjournals.bsky.social
In the November 1 issue of Clinical Cancer Research, read the Phase 1 Study: Izalontamab in advanced epithelial tumor.
Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
AbstractPurpose:. Izalontamab (SI-B001) is a novel EGFR×HER3 bispecific antibody. This first-in-human phase I study presents the safety and pharmacokinetics of izalontamab.Patients and Methods:.…
buff.ly
November 22, 2025 at 5:01 PM
ie-news.bsky.social
First-in-Human Data Support Izalontamab in Advanced Epithelial Tumors | Targeted Oncology

https://www.europesays.com/ie/168684/

Izalontamab (SI-B001), a novel EGFR/HER3 bispecific monoclonal antibody, was well-tolerated and exhibited preliminary antitumor activity in previously treated…
First-in-Human Data Support Izalontamab in Advanced Epithelial Tumors | Targeted Oncology - Ireland
Izalontamab (SI-B001), a novel EGFR/HER3 bispecific monoclonal antibody, was well-tolerated and exhibited preliminary antitumor activity in previously treated
www.europesays.com
November 7, 2025 at 10:30 PM
vcclibrary.bsky.social
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China. www.thelancet.com/journals/lan...
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, ope...
Iza-bren significantly improved the ORR compared with chemotherapy in individuals with heavily pretreated recurrent or metastatic nasopharyngeal carcinoma, with a manageable safety profile. These find...
www.thelancet.com
October 23, 2025 at 1:23 PM
onclive.bsky.social
Izalontamab Brengitecan Data Reinforce the Value of ADCs in Advanced #UrothelialCarcinoma. #oncology #ADCs

www.onclive.com/view/izalont...
Izalontamab Brengitecan Data Reinforce the Value of ADCs in Advanced Urothelial Carcinoma | OncLive
Izalontamab brengitecan showed signals of activity in patients with pretreated locally advanced or metastatic urothelial carcinoma.
www.onclive.com
October 15, 2025 at 6:42 PM
au-nb.bsky.social
SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform

https://www.newsbeep.com/au/174822/

REDMOND, Wash., Sept. 24, 2025 /PRNewswire/ — SystImmune, Inc. (SystImmune), a clinical-stage …
SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform - Australia News Beep
REDMOND, Wash., Sept. 24, 2025 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of data
www.newsbeep.com
September 28, 2025 at 9:45 AM
thecancersurvivorsclub.com
FDA grants Breakthrough Therapy Designation to izalontamab brengitecan (iza-bren) for advanced NSCLC patients—potential new hope in lung cancer treatment. #TCSC #LungCancer #CancerResearch #FDA

pharmatimes.com/news/fda-gra...
FDA grants Breakthrough Therapy Designation to lung cancer therapy - PharmaTimes
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren), an investigational drug
pharmatimes.com
August 20, 2025 at 7:18 AM
au-nb.bsky.social
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

https://www.newsbeep.com/au/77946/

First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol …
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Australia News Beep
First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb's Izalontamab brengitecan (Iza-bren) based on data from the
www.newsbeep.com
August 18, 2025 at 6:00 PM
onclive.bsky.social
FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan in EGFR+ NSCLC
@fda.gov #NSCLC #LCSM
www.onclive.com/view/fda-gra...
FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan in EGFR+ NSCLC
Izalontamab brengitecan earned FDA breakthrough therapy designation for EGFR-mutated locally advanced or metastatic NSCLC.
www.onclive.com
August 18, 2025 at 3:19 PM
rcatanho.bsky.social
Izalontamab brengitecan, anticuerpo monoclonal biespecífico dirigido a EGFR y HER3, mejora resultados en pacientes con carcinoma nasofaríngeo avanzado que no responden al menos a dos líneas de quimioterapia con platino luego de recibir un anticuerpo anti-PD-L1 firstwordpharma.com/story/5977722
FirstWord
firstwordpharma.com
July 7, 2025 at 5:08 AM